Top Markets
#1 EXOD EXOD +56.80%
#2 MowCat MowCat +48.06%
#3 CoW Protocol CoW Protocol +37.63%
#4 Glidr Glidr +36.87%
#5 Humanity Humanity +28.04%
#6 Walrus Walrus +22.05%
#7 Codatta Codatta +21.20%
#8 Enso Enso +19.64%
#9 The Black Bull The Black Bull +17.55%
#10 Tutorial Tutorial +14.31%
Coin of the day
EXOD EXOD
Settings
Language
ENGLISH
Currency
USD
Theme
Carmell Therapeutics Corporation Carmell Therapeutics Corporation

Carmell Therapeutics Corporation

CTCX
Rank in Stocks #36666
Carmell Therapeutics Corporation (CTCX) specializes in the creation of... Carmell Therapeutics Corporation (CTCX) specializes in the creation of plasma-based bioactive materials (PBMs) aimed at catalyzing tissue regeneration and repair following injury, illness, or the effects of aging. Their flagship product, CT-101, is a versatile accelerant with a dual focus. For orthopedic and dental applications, it's designed to enhance bone healing in cases such as tibia fractures, foot and ankle fusions, spinal fusions, and also serves as a dental bone graft substitute and bone void filler. Furthermore, CT-101 acts as a tissue healing accelerant, addressing conditions like androgenetic alopecia (pattern baldness) and persistent chronic wounds. Established in 2008, the company operates from its headquarters in Pittsburgh, Pennsylvania.
Share Price
$0.117
Last synced: 2025-04-04
Market Cap
$2.45M
Change (1 day)
-13.59%
Change (1 year)
0.00%
Country
US
Trade Carmell Therapeutics Corporation (CTCX)

Category

Healthcare
P/B ratio for Carmell Therapeutics Corporation (CTCX)
P/B ratio as of August 2026 TTM: -0.06
According to Carmell Therapeutics Corporation latest financial reports and stock price the company's current price-to-book ratio (TTM) is -0.06. At the end of 2023 the company had a P/B ratio of 95.93.
P/B ratio history for Carmell Therapeutics Corporation from 2021 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
2026 (TTM) -0.06 -99.85%
2024 -37.13 -138.70%
2023 95.93 -161.62%
2022 -155.68 -19.29%
2021 -192.90 0.00%
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -11,404.63%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -11,225.31%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.4612 -6,269.70%
BE